Merger Expected to Accelerate Development of Personalized Medicine Solutions

(Redwood City, CA, USA).

Bina’s integrated, scalable, and comprehensive analysis platform, Genomic Management Solution or Bina-GMS1, empowers clinical and academic researchers to gain insight from their genomics data sets by dramatically decreasing the complexity, time, and cost of the analysis, accelerating the science of personalized medicine. The Bina Genome Analysis Platform includes a cancer pipeline that implements an integrative approach to identify and rank the most clinically important mutations based on a combination of different algorithms, sequencing features, and prior knowledge.

"The acquisition of Bina is a significant step for Roche to enable the promise of personalized healthcare by delivering the highest quality genomic data possible," said Dan Zabrowski, head of sequencing at Roche. "Informatics and data management are critical to providing a seamless, end-to-end sequencing solution. Bina's products are designed to improve the efficiency and value of genomic analysis, and the company continues to develop new methodologies and algorithms that link NGS data to disease-relevant genetic markers."

"Roche's acquisition of Bina is a great validation of our work and technology. It is also an indication of how informatics and data science are going to play a major role in the future of medicine," said Narges Bani Asadi, CEO of Bina. "We found great alignment between our company's vision and values, and we are very excited about the possibilities of working with Roche's global team and serving academic, translational, and clinical research markets together in the future."

It is expected that the acquisition by Roche will enable Bina to accelerate product development and global commercialization of Bina-GMS as an enterprise software system supporting multiple sequencing technologies while developing a solution for Roche sequencing systems.

Related Links:
Roche
Bina Technologies, Inc.